Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a biopharmaceutical company focused on developing innovative therapies in oncology and obesity, recently made significant announcements concerning its robust research initiatives at two prominent scientific gatherings. The company showcased new pre-clinical data for its CB1 inverse agonist, CRB-913, at Obesity Week 2024, while also highlighting updates on its groundbreaking antibody-drug conjugate, CRB-701 (SYS-6002), set to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting.
CRB-913: Targeting Obesity with Peripherally Restricted Mechanisms
At Obesity Week 2024, held in early November, Corbus Pharmaceuticals presented compelling pre-clinical findings regarding CRB-913, a novel compound designed as a highly peripherally restricted CB1 inverse agonist. The data presented, encapsulated in a poster
Comments